A 55-year-old man with COPD exacerbation is on triple inhaled therapy (LAMA + LABA + ICS). His GOLD classification is Group D. Despite optimal inhaler therapy, he has had 3 hospitalizations in the past year. What additional therapy is indicated per GOLD 2023 report?
- A Roflumilast (PDE-4 inhibitor) if FEV1 <50% predicted, chronic bronchitis, and frequent exacerbations ✓
- B Azithromycin 250 mg daily for 1 year regardless of smoking status
- C Oral prednisolone 10 mg daily to prevent further exacerbations
- D Theophylline 200 mg BD as fourth bronchodilator add-on
Explanation
GOLD 2023 recommends roflumilast add-on therapy for COPD patients with FEV1 <50% predicted, a chronic bronchitis phenotype, and two or more moderate exacerbations or one hospitalization per year despite optimized bronchodilator therapy. Roflumilast (PDE-4 inhibitor) reduces airway inflammation by elevating intracellular cyclic AMP. Azithromycin prophylaxis (250 mg daily or 500 mg three times weekly) is an option in non-smoking ex-smokers but requires QTc monitoring; it is not preferred over roflumilast in bronchitis phenotype. Long-term oral corticosteroids are harmful and not recommended.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.